Sangamo Therapeutics (SGMO) Misses Q1 EPS by 71c, Miss on Revenues

Sangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.23), $0.71 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $12.64 million versus the consensus estimate of $53.09 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2